Peregrine Asset Advisers Inc. Acquires New Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Peregrine Asset Advisers Inc. acquired a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) during the third quarter, Holdings Channel reports. The fund acquired 11,795 shares of the medical equipment provider’s stock, valued at approximately $5,795,000. Intuitive Surgical accounts for approximately 2.0% of Peregrine Asset Advisers Inc.’s investment portfolio, making the stock its 11th largest position.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ISRG. Ashton Thomas Securities LLC boosted its holdings in Intuitive Surgical by 12.7% in the 3rd quarter. Ashton Thomas Securities LLC now owns 3,405 shares of the medical equipment provider’s stock valued at $1,673,000 after purchasing an additional 384 shares during the last quarter. Los Angeles Capital Management LLC raised its position in shares of Intuitive Surgical by 230.5% during the 3rd quarter. Los Angeles Capital Management LLC now owns 53,789 shares of the medical equipment provider’s stock valued at $26,425,000 after buying an additional 37,516 shares during the period. Mitchell Mcleod Pugh & Williams Inc. lifted its holdings in Intuitive Surgical by 4.1% in the third quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 503 shares of the medical equipment provider’s stock valued at $247,000 after acquiring an additional 20 shares during the last quarter. Meritage Portfolio Management acquired a new stake in Intuitive Surgical during the third quarter worth $210,000. Finally, Tyler Stone Wealth Management raised its position in Intuitive Surgical by 107.1% in the third quarter. Tyler Stone Wealth Management now owns 1,284 shares of the medical equipment provider’s stock valued at $631,000 after purchasing an additional 664 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Trading Up 2.3 %

ISRG stock opened at $536.45 on Monday. The stock has a market cap of $191.07 billion, a P/E ratio of 86.25, a PEG ratio of 5.27 and a beta of 1.39. Intuitive Surgical, Inc. has a twelve month low of $269.49 and a twelve month high of $538.49. The company’s 50 day moving average is $493.92 and its two-hundred day moving average is $452.79.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.24 by $0.32. The company had revenue of $2.04 billion during the quarter, compared to analysts’ expectations of $2.01 billion. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. On average, equities research analysts predict that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on ISRG shares. Citigroup boosted their price objective on shares of Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. Evercore ISI restated a “cautious” rating on shares of Intuitive Surgical in a report on Friday, October 18th. BTIG Research set a $535.00 target price on Intuitive Surgical in a research report on Friday, October 18th. Mizuho upped their price target on Intuitive Surgical from $440.00 to $500.00 in a research note on Thursday, October 17th. Finally, Raymond James boosted their price objective on Intuitive Surgical from $500.00 to $540.00 and gave the company an “outperform” rating in a report on Monday, October 14th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and an average target price of $513.74.

Insider Buying and Selling

In other news, Director Amy L. Ladd sold 450 shares of the company’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $490.28, for a total value of $220,626.00. Following the completion of the sale, the director now directly owns 821 shares of the company’s stock, valued at approximately $402,519.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Amy L. Ladd sold 450 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $490.28, for a total transaction of $220,626.00. Following the completion of the sale, the director now owns 821 shares in the company, valued at $402,519.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Henry L. Charlton sold 40,243 shares of Intuitive Surgical stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the transaction, the senior vice president now owns 3,001 shares in the company, valued at approximately $1,461,006.84. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 68,006 shares of company stock worth $33,727,766 in the last 90 days. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.